Immix Biopharma, Inc.
Immix Biopharma, Inc. (IMMX) Revenue
Annual & quarterly revenue history · segment & region breakdown
IMMX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsImmix Biopharma, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Immix Biopharma, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Immix Biopharma, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Immix Biopharma, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IMMX revenue · 4 questionsIMMX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Immix Biopharma, Inc. SEC filings · GAAP · Immix Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026